Cognitiv (Selegiline) is commonly used to provide supportive symptomatic relief across key therapeutic areas, including movement disorders and specific forms of mood disorders. The medication is commonly used in the management of Parkinson’s Disease and Major Depressive Disorder.

Cognitiv is considered relevant in managing Parkinson's Disease, and may assist with addressing symptom clusters that may become intense or disruptive, such as symptoms of increased neurological or muscular activity (like slowness and stiffness). It is applied in addressing conditions involving episodic or fluctuating manifestations, and contributes to easing the overall symptom load. For patients with newly diagnosed, mild symptoms, it may be part of symptomatic management when supportive symptom management is appropriate.

“The benefit provided is supportive relief that helps patients cope more steadily with difficult symptoms that interfere with daily comfort.”

In a separate domain, the medication is relevant for easing symptoms of Major Depressive Disorder, in conditions characterized by periods of heightened symptoms that are difficult to address. The benefit provided is supportive relief that helps improve day-to-day comfort during symptomatic periods.

---

Key Use: Motor Fluctuation and Early Symptom Support

Regulatory References

1. NIH StatPearls overview

Who can and cannot use Cognitiv?

Cognitiv (Selegiline) is approved for use in adults for its labeled indications. However, government regulatory documents define strict population criteria for non-eligibility and restricted use.

The medicine is contraindicated and must not be used by patients with known hypersensitivity to selegiline or an active duodenal or gastric ulcer. Absolute non-eligibility also applies to patients concurrently receiving certain medications, including specific opioid drugs (such as meperidine), SSRIs, SNRIs, tricyclic antidepressants, or other MAO inhibitors. Contraindications may extend to conditions like severe cardiovascular disease or advanced dementia when the medicine is used in combination with levodopa.

Use is generally not established in the pediatric population (children and adolescents), and the transdermal patch is contraindicated in children under 12 years of age.

Further restrictions apply to organ function and physiological states. Use is not recommended in cases of severe hepatic or renal impairment. For reproductive health, use is preferable to avoid during pregnancy and should not be used by breastfeeding mothers. Additionally, the orally disintegrating tablet (ODT) formulation must be avoided by patients with Phenylketonuria (PKU) due to the presence of phenylalanine.

Interactions with Other Medicines and Products

The interaction profile of Selegiline is defined by strict regulatory constraints established to prevent severe pharmacodynamic effects.

Contraindicated Combinations (Prohibited)

Co-administration with Selegiline is formally contraindicated due to the risk of severe toxicity, including Serotonin Syndrome or Hypertensive Crisis. Prohibited substances include other Monoamine Oxidase Inhibitors (MAOIs), serotonergic agents like Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs), Opioid Analgesics (such as Meperidine and Tramadol), Triptans, and Sympathomimetic Agents. Certain herbal products (e.g., St. John's wort) are also strictly prohibited.

Regulatory Timing and Substance Constraints

A mandatory 14-day washout period is required between the discontinuation of Selegiline and the initiation of any prohibited serotonergic drugs. Exposure-modifying interactions are documented with Oral Contraceptives, which can increase the drug's bioavailability; therefore, their co-administration should be avoided. Dose-dependent dietary restrictions apply: consumption of Tyramine-Rich Foods is officially restricted for specific higher doses of both the oral and transdermal forms. The use of Alcohol (Ethanol) is officially stated as needing to be avoided due to the potential for potentiated central nervous system depressant effects. Additionally, caution is advised in patients with severe hepatic impairment due to the potential for higher plasma concentrations of the drug.

How Cognitiv Works

Cognitiv (Selegiline) functions as a highly selective, irreversible inhibitor of the Monoamine Oxidase Type B (MAO-B) enzyme in the central nervous system (CNS). This mitochondrial enzyme is primarily responsible for the metabolic breakdown, or catabolism, of the neurotransmitter dopamine. By forming a stable, covalent bond with the MAO-B molecule, the drug permanently inactivates the enzyme.

This pathway interference leads to the preservation and increase of dopamine availability in the synaptic clefts, representing the primary physiological change. The resulting elevated and sustained dopamine levels facilitate increased signal transmission across key neural pathways. The sustained functional effect is dictated by the slow biological rate of new MAO-B enzyme synthesis, ensuring prolonged functional modulation of dopaminergic signaling. This mechanism also establishes a pharmacological synergy with co-administered dopamine precursors, where the drug extends the functional duration of the precursor by interfering with metabolic clearance.

The use of Cognitiv (Selegiline Hydrochloride) follows administration guidelines that vary based on the dosage form and the target condition. The medicine is available as oral capsules/tablets and as a transdermal patch system.

---

Administration Routes and Schedule

Dosage Form	Frequency Pattern	Key Administration Context
Oral Capsules/Tablets (5 mg)	Twice daily	Must be taken with food, typically at breakfast and lunch.
Oral Disintegrating Tablets (ODT)	Once daily	Taken before breakfast. Food and liquids must be avoided for 5 minutes before and after administration.
Transdermal Patch (6–12 mg/24 hours)	Once daily	Applied to dry, intact skin; application sites must be rotated.

---

Dosing and Adjustments

For Parkinson’s Disease, the standard oral tablet regimen is 5 mg twice a day, while the ODT starting dose is 1.25 mg once a day, which can be increased to 2.5 mg after at least six weeks. For Major Depressive Disorder, the transdermal patch starts at 6 mg/24 hours and can be adjusted in 3 mg/24 hour increments at intervals of no less than two weeks, up to a maximum of 12 mg/24 hours. Dosage reduction to 1.25 mg once daily is required for the ODT formulation in patients with mild-to-moderate hepatic impairment. Use of the ODT form is not recommended in patients with severe renal dysfunction. Crucially, the 9 mg/24 hours and 12 mg/24 hours patch doses necessitate mandatory tyramine dietary restrictions.

Evidence for use in Parkinson’s Disease

Research explores Cognitiv's use in individuals newly diagnosed with the condition and was studied in patients already receiving levodopa therapy who experience symptom fluctuations. The primary evidence consists of short-term, randomized, placebo-controlled trials (RCTs), supported by long-term observational extension studies. Researchers track changes using the Unified Parkinson's Disease Rating Scale (UPDRS) and examine the time interval before levodopa initiation was observed, and changes in the required levodopa dose in adjunct studies. Findings describe patterns observed in the studies related to symptom reduction and delayed levodopa use. Research exploring potential long-term disease progression or effects on nerve health remains unestablished by definitive controlled studies.

---

Evidence for use in Major Depressive Disorder (Transdermal Patch)

Evidence for the transdermal patch formulation is based on short-term RCTs and controlled maintenance trials for Major Depressive Disorder (MDD). Studies monitor symptom change using scales like the Hamilton Depression Rating Scale (HDRS) and track the maintenance of symptom response for up to nearly one year. The evidence base includes inconsistent results across some acute symptom change trials, meaning some studies reported measurements showing a larger difference compared to placebo while others did not.

---

Key Research Gaps and Uncertainties

The body of research available is limited primarily to short-term outcomes. Evidence exploring potential long-term disease progression is not yet conclusive. Furthermore, data for certain complex groups, such as pregnant individuals or those with complex medical histories, remain insufficient or unpublished. In trials that examined the adolescent population, the findings were varied, and the research does not provide individual predictions about how a specific person in a specific group may respond.

Key Studies & References Parkinson's disease in adults: diagnosis and management (NICE Guideline NG71)

Common questions about Cognitiv (FAQ)

Q: Have there been long-term studies published about Cognitiv's effects?

Official research evidence includes short-term trials and is supported by observational extension studies conducted over longer periods. However, conclusive data exploring the potential for long-term effects on disease progression or nerve health remains unestablished by definitive controlled studies.

Q: Is Cognitiv safe to use for older adults?

Official regulatory safety profiles acknowledge that side effects like dizziness, lightheadedness, and a drop in blood pressure upon standing (orthostatic hypotension) may be more frequently reported when older adults first begin treatment. This information highlights the need for caution, which should be discussed with a healthcare provider.

Q: Can children or teenagers use Cognitiv?

Cognitiv is approved for use in adults for its indicated conditions. The medicine's use is generally not established in the pediatric population, and the transdermal patch is formally contraindicated for children under 12 years of age. Research findings in the adolescent population have been noted by authorities as varied.

Q: Why do doctors need to monitor certain lab tests while taking Cognitiv?

Clinical monitoring, including blood tests, may be required to check for possible unwanted effects. This is particularly relevant because official guidance states the medicine is not recommended for patients who have severe impairment of liver or kidney function.

Q: Do I need to take Cognitiv with food?

The requirements for administration with food depend on the specific formulation. Official guidelines state that oral capsules or tablets must be taken with food, typically at breakfast and lunch. For the orally disintegrating tablet (ODT) formulation, the official instruction is to take it before breakfast, with avoidance of food and liquids specified for 5 minutes before and after administration.

Q: Does Cognitiv need to build up in my system to start working?

The official mechanism of action involves permanently blocking the MAO-B enzyme, which prevents the breakdown of dopamine. The sustained functional effect of the medicine is dictated by the slow biological rate at which the body produces new enzyme. This suggests a physiological process that occurs over time.

Q: What happens if I forget to take my dose of Cognitiv?

Official patient information describes the recommended approach for managing a missed dose. The guidance indicates the dose may be taken as soon as it is remembered, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped. The regulatory guidance cautions against taking double the prescribed amount.

Q: Are the side effects of Cognitiv temporary or do they last a long time?

The safety profile notes that some side effects are more likely to occur when a patient first begins taking the medicine. For instance, the drop in blood pressure upon standing is noted as being more common during the initial period of treatment.

Q: Is it normal to feel slightly nauseous after starting Cognitiv?

Official safety information classifies nausea as a 'Very Common' adverse reaction. This documentation indicates that the experience has been reported to affect 1 in 10 people or more during clinical trials with the medicine.

Q: Can Cognitiv cause weight gain or weight loss?

The official safety profile for the medicine lists anorexia, or loss of appetite, as a Very Common adverse reaction. This side effect is commonly associated with resulting weight loss.

Q: Does Cognitiv affect my ability to drive or operate machinery?

Official safety warnings note that the medicine's documented side effects include dizziness, involuntary movements (dyskinesia), and trouble sleeping. Due to the presence of these effects, caution is generally recommended regarding activities that require mental alertness, such as driving or operating heavy machinery.

Q: Are there any specific foods or drinks I need to avoid while on Cognitiv?

Official guidance states that the use of alcohol (Ethanol) is required to be avoided. Furthermore, consumption of Tyramine-Rich Foods is officially restricted, but this restriction only applies when patients are prescribed specific higher doses of the oral or transdermal forms.

Q: Is Cognitiv considered a 'strong' or 'mild' medication?

The medicine is officially classified as a Selective Monoamine Oxidase Type B (MAO-B) Inhibitor. This pharmacological mechanism is associated with strict regulatory constraints regarding co-administration with other medicines, including several formal contraindications due to the potential for severe reactions.

Q: What should I do if I think I am having a severe reaction to Cognitiv?

Official patient information provides guidance on severe reactions. Signs such as a severe headache, confusion, high blood pressure, or sudden changes in behavior are described as warranting immediate reporting to a physician.

Q: Are there any mental health conditions that prevent someone from using Cognitiv?

The use of Cognitiv is formally contraindicated (prohibited) when a patient is concurrently receiving certain serotonergic medicines, such as specific antidepressants, commonly used for mental health conditions. This is due to the potential risk of a serious reaction called Serotonin Syndrome.

Q: Is Cognitiv chemically related to other similar medicines?

Official regulatory classification defines the active ingredient, Selegiline, as a Selective Monoamine Oxidase Inhibitor. It is also categorized and recognized alongside other Antiparkinsonian Agents, defining its chemical and functional relationship to medicines within these classes.

Q: Why is Cognitiv sometimes preferred over other drugs for this condition?

Regulatory product information highlights the medicine's versatility as a key differentiator. The inclusion of a transdermal patch system, in addition to oral forms, provides a unique administration route compared to some other oral Antiparkinsonian Agents.

Q: Does Cognitiv come in different strengths or formulations?

The medicine is available in various forms, including conventional oral capsules/tablets, orally disintegrating tablets (ODT), and a specialized transdermal patch system. Official guidelines document multiple specific strengths available for each of these formulations.

Q: What if I take too much Cognitiv by accident?

The official prescribing information documents the potential symptoms of an overdose, which may include signs such as severe headache, agitation, convulsions, and extreme drowsiness. Treatment involves general supportive care and measures to eliminate the undigested drug.

Q: Why do some people report feeling tired when they first start Cognitiv?

According to official safety reporting, both sleepiness (somnolence) and unusual tiredness or weakness are documented as reported adverse reactions to the medicine. This is a common pattern for many medicines that affect the central nervous system.

Q: Does Cognitiv change how other medicines are absorbed?

Official documents describe exposure-modifying interactions. Regulatory information specifically notes that co-administration with oral contraceptives can increase the bioavailability, or absorption rate, of Cognitiv itself.

Q: Can Cognitiv be taken during pregnancy?

Official regulatory guidance advises that use of the medicine is preferable to avoid during pregnancy. This statement is based on the available data regarding use during this period.

Q: If I miss a few doses of Cognitiv, will the condition worsen?

Official warnings caution against the rapid dose reduction or abrupt discontinuation of the medicine. Regulatory documents note that stopping the drug suddenly may cause some underlying conditions to worsen.

Q: Are there any age restrictions for taking Cognitiv?

The medicine is approved for use in adults for its labeled indications. Regulatory documents provide specific age-based restrictions, including non-eligibility criteria for the pediatric population and a formal contraindication for the transdermal patch in children under 12.

Q: What should I do if Cognitiv doesn't seem to be working?

Official patient information indicates that if the medication appears to stop working effectively or if the underlying condition seems to be getting worse, this observation should be discussed with the prescribing doctor.

Q: Can Cognitiv affect my blood pressure?

The medicine is associated with documented blood pressure changes. These include orthostatic hypotension (a drop in blood pressure when standing up) as a Common side effect, and the potential for a serious reaction called a Hypertensive Crisis at doses higher than those recommended.

Q: What happens if I take Cognitiv close to bedtime?

Official patient warnings advise against taking the medicine late in the day. The safety profile documents insomnia (difficulty falling asleep) as a very common side effect, which informs this guidance.

Q: Is Cognitiv a controlled substance?

The regulatory classification of the active ingredient, Selegiline, confirms that it is not listed as a controlled substance in the U.S. system. It is recognized as a prescription-only medicine.

How to Store and Dispose of Cognitiv (Selegiline)

Storage Component	Official Requirement
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C.
Protection	Oral forms must be protected from moisture. Transdermal patches must be protected from light and must not be refrigerated or frozen.
Packaging	Oral forms must be stored in the original, tightly closed container. Patches must remain in their sealed pouch until application.
Child Safety	All forms must be stored out of the sight and reach of children.

Official Disposal Rules

Unused or expired Selegiline must not be disposed of via wastewater or household waste and should be discarded according to local requirements for pharmaceutical waste. Used transdermal patches must be folded sticky-sides together immediately after removal and placed securely out of the reach of children and pets.